Novo Nordisk loses further ground in obesity market
Danish drugmaker expects sales and profit growth at lower end of its guidance this year
Related reading
Novo Nordisk calls for US import ban on key ingredient for obesity drug copycats
Danish group loses share in diabetes drugs to rivals, with first-half sales growth easing to 8%
Novo Nordisk’s new ‘king’ tightens his grip at obesity drug giant
Boardroom shake-up at European drugmaker grants Lars Rebien Sørensen wide-ranging powers
Novo Nordisk faces more gloom from price cuts in crowded anti-obesity drugs…
Danish group’s challenges mount despite winning reprieve after Hims & Hers withdraws plan to sell copycat Wegovy pill
Novo Nordisk shares drop 15% after poor trial results for new obesity drug
Once-a-week injection achieved less weight loss than rival treatment
Novo Nordisk again raises bid in battle for obesity start-up Metsera
Danish company vies with Pfizer for control of US biotech as they seek edge in growing market for weight-loss drugs
Pharma just ‘scratching the surface’ of weight-loss drug market
Novo Nordisk chief estimates industry reaching only 15% of potential customers at most